

Clinical Policy: Short Ragweed Pollen Allergen Extract (Ragwitek)

Reference Number: ERX.NPA.71

Effective Date: 09.01.18

Last Review Date: 08.21

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Short ragweed pollen allergen extract (Ragwitek[®]) is an allergen extract.

FDA Approved Indication(s)

Ragwitek is indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in persons 5 through 65 years of age.

Ragwitek is not indicated for the immediate relief of allergic symptoms.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Ragwitek is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Allergic Rhinitis (must meet all):

1. Diagnosis of short ragweed pollen-induced allergic rhinitis;
2. Prescribed by or in consultation with an allergist or immunologist;
3. Age \geq 5 years and \leq 65 years;
4. Confirmation of a positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen;
5. Failure of one intranasal corticosteroid, unless clinically significant adverse effects are experienced or all are contraindicated;
6. Failure of one oral antihistamine at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;
7. Dose does not exceed 1 tablet per day.

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Allergic Rhinitis (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 1 tablet per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria.

The drugs listed here may not be a formulary agent and may require prior authorization.

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|--|--|---|
| cetirizine (Zyrtec [®]) | 2 to 5 years: 2.5-5 mg PO QD ≥ 6 years: 10 mg PO QD | 10 mg/day |
| desloratadine (Clarinet [®]) | 2 to 5 years: 1.25 mg PO QD 6 to 11 years: 2.5 mg PO QD ≥ 12 years: 5 mg PO QD | 5 mg/day |
| levocetirizine (Xyzal [®]) | 6 to 11 years: 2.5 mg PO QD ≥ 12 years: 5 mg PO QD | 5 mg/day |
| budesonide (Rhinocort [®] Aqua) | 6 to 11 years: 1-2 sprays each nostril QD ≥ 12 years: 1-4 sprays each nostril QD | 4 sprays each nostril/day |
| fluticasone propionate (Flonase [®]) | ≥ 4 years: 1-2 sprays each nostril QD ≥ 12 years: 1-2 sprays each nostril QD | 2 sprays each nostril/day |
| triamcinolone acetonide (Nasacort AQ [®]) | 2-11 years: 1 spray each nostril QD ≥ 12 years: 1-2 sprays each nostril QD | 2-11 years: 1 spray each nostril/day > 12 years: 2 sprays each nostril/day |
| mometasone furoate monohydrate (Nasonex [®]) | 2-11 years: 1 spray each nostril QD ≥ 12 years: 2 sprays each nostril QD | 2-11 years: 1 spray each nostril/day > 12 years: 2 sprays each nostril/day |

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): severe, unstable or uncontrolled asthma; history of eosinophilic esophagitis; history of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy; hypersensitivity to any of the inactive ingredients contained in this product
- Boxed warning(s): severe allergic reactions

V. Dosage and Administration

| Indication | Dosing Regimen | Maximum Dose |
|--|------------------|--------------|
| Short ragweed pollen-induced allergic rhinitis | One tablet SL QD | 1 tablet/day |

| Indication | Dosing Regimen | Maximum Dose |
|------------|--|--------------|
| | Treatment should be initiated at least 12 weeks before the expected onset of ragweed pollen season and continue treatment throughout the season. | |

VI. Product Availability

Tablet: 12 Amb a 1-Unit (Amb a 1-U)

VII. References

1. Ragwitek Prescribing Information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; April 2021. Available at: <https://www.ragwitek.com>. Accessed April 27, 2021.
2. Wallace DV, Dykewicz MS, Oppenheimer J et al. Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017 Dec 19;167(12):876-881. doi: 10.7326/M17-2203.
3. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43. doi: 10.1177/0194599814561600.
4. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CC, Schuller D, Spector SL, Tilles SA, Joint Task Force on Practice, American Academy of Allergy, Asthma&Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1-84.
5. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55.
6. Brozek, JL, Bousquet J, Agache I et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Oct;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050.
7. Greenhawt M, Oppenheimer J, Nelson M, et al. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update. Ann Allergy Asthma Immunol. 2017; 118: 276-282.
8. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020; 136(4): 721-767.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|---|----------|-------------------|
| Policy created. | 05.02.18 | 08.18 |
| 3Q 2019 annual review: no significant changes; corrected age restriction from < 65 years to ≤ 65 years per PI; references reviewed and updated. | 04.22.19 | 08.19 |
| 3Q 2020 annual review: no significant changes; references reviewed and updated. | 04.06.20 | 08.20 |
| 3Q 2021 annual review: no significant changes; RT4: revised age restriction from 18-65 years to 5-65 years per updated FDA indication; references reviewed and updated. | 03.22.21 | 08.21 |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

CLINICAL POLICY
Short Ragweed Pollen Allergen Extract

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2018 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.